KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents (2016 - 2025)

Neogenomics (NEO) has disclosed Cash & Equivalents for 16 consecutive years, with $164.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 54.66% year-over-year to $164.1 million, compared with a TTM value of $164.1 million through Sep 2025, down 54.66%, and an annual FY2024 reading of $367.0 million, up 7.16% over the prior year.
  • Cash & Equivalents was $164.1 million for Q3 2025 at Neogenomics, up from $154.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $612.0 million in Q1 2021 and bottomed at $154.7 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $318.5 million, with a median of $316.8 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents soared 609.5% in 2021, then crashed 56.43% in 2025.
  • Year by year, Cash & Equivalents stood at $316.8 million in 2021, then decreased by 16.93% to $263.2 million in 2022, then surged by 30.13% to $342.5 million in 2023, then grew by 7.16% to $367.0 million in 2024, then tumbled by 55.28% to $164.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for NEO at $164.1 million in Q3 2025, $154.7 million in Q2 2025, and $346.2 million in Q1 2025.